Published in Hematology Week, December 19th, 2005
The results showed that adding Integrelin, a potent glycoprotein (GP) IIb-IIIa inhibitor, to a loading dose of clopidogrel, a commonly used oral antiplatelet therapy, produced superior reduction in inflammation in patients undergoing elective percutaneous coronary intervention (PCI) stenting. In this study, the degree of inflammation was assessed by levels of tumor necrosis factor (TNF)-alpha and C-reactive protein (CRP) and other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.